Resveratrol Is Almost Impossible to Absorb: The Bioavailability Disaster Nobody Talks About

Resveratrol has one of the longest hype-to-evidence gaps of any supplement on the shelf. It went mainstream after a 2003 paper showed it extended yeast lifespan through activation of a class of enzymes called sirtuins. A wave of mouse studies followed. A red-wine industry marketing angle was launched. By the late 2000s "the molecule in red wine that makes you live longer" was on every anti-aging shelf, in every nootropic stack, and in every cardiovascular support formula in the country. The 500 mg and 1000 mg capsules on the shelf were sold on the strength of those animal studies and the promise that oral supplementation would translate the effect.

It largely does not. And the reason it does not is not that the underlying pharmacology is fake — SIRT1 activation is real, the antioxidant profile is real, the cardiovascular endothelial effects at pharmacological blood levels are real. The reason is that oral resveratrol is one of the least bioavailable molecules ever aggressively marketed as an oral supplement. The pharmacokinetic literature on this has been consistent for over a decade, and the industry has responded by adjusting label doses upward — 500 mg, 1000 mg, "1500 mg complex" — rather than confronting the underlying absorption problem, because a bigger label number sells more capsules than a smaller honest one.

This post walks through what oral resveratrol actually does in humans, why the label number does not equal the blood level, what the "alternative form" products (micronized, liposomal, SR, pterostilbene, polydatin) actually change about the numbers, and how to decide whether the supplement is worth taking at all.

What resveratrol is, briefly

Resveratrol is a stilbene — a small polyphenol — produced by certain plants (grape skins, Japanese knotweed root, peanuts, some berries) as a defense compound against fungal infection. Two isomers exist: trans-resveratrol and cis-resveratrol. Only the trans form has meaningful biological activity. Any credible product should be standardized to trans-resveratrol content; the total-resveratrol number on some labels includes the biologically inert cis fraction and is inflated.

Mechanistically, resveratrol at pharmacological concentrations activates SIRT1 (a NAD+-dependent deacetylase involved in mitochondrial biogenesis, autophagy, and metabolic regulation), inhibits cyclooxygenase and lipoxygenase enzymes, scavenges reactive oxygen species, modulates NF-kB signaling, and affects a broad panel of transcription factors. In cell culture at 10-50 micromolar concentrations it does interesting things. In animals dosed at 100 mg/kg to 400 mg/kg — doses that produce measurable tissue concentrations because rodent gut metabolism and body size differ from ours — it also does interesting things.

In humans dosed orally at 500 mg to 5000 mg, plasma free resveratrol peaks somewhere between 10 and 500 nanomolar and drops back to baseline within 4 to 8 hours. That is one to three orders of magnitude below the concentrations at which any of the interesting mechanisms fire in a cell culture dish.

The absorption problem: what happens to oral resveratrol in the first hour

Resveratrol is absorbed reasonably well from the gut — total absorption of an oral dose (parent compound plus metabolites) is around 70% based on isotope studies. That is not the problem. The problem is what happens next.

Once resveratrol crosses the gut wall, enterocytes rapidly conjugate it with sulfate groups via sulfotransferase enzymes and with glucuronic acid via UDP-glucuronosyltransferases. What arrives at the portal vein is already mostly resveratrol-3-O-sulfate and resveratrol-3-O-glucuronide — not the free molecule. The liver then processes the small remaining free fraction through the same conjugation pathways, and by the time the compound reaches systemic circulation, over 95% of it is in the form of these two conjugated metabolites.

Plasma concentrations of free trans-resveratrol after a 500 mg oral dose in healthy adults peak around 10-40 nanomolar at 1 hour and drop back near baseline by 4 hours. A 2500 mg dose (five capsules of a typical product) pushes the peak to maybe 300-500 nanomolar for an hour, still with a fast decline. A 5000 mg single dose has been studied — plasma peaks around 500 nanomolar to 2 micromolar, GI side effects (nausea, cramping, diarrhea) become common, and the peak still does not sustain for more than a few hours.

For context: the SIRT1 activation experiments in cell culture that drove the entire hype cycle used concentrations in the 10-50 micromolar range. Even the most aggressive oral dose humans have tolerated does not reach 5% of that concentration, and only briefly.

The sulfate and glucuronide metabolites do have some biological activity of their own — they can be deconjugated in certain tissues, they may act as slow-release depot forms of the parent compound, and some have their own weak direct activities. But the pharmacology of the conjugates is not the pharmacology of free resveratrol, and the trials that show cardiovascular endothelial improvements or metabolic effects in humans generally involve doses at the high end (500-2500 mg/day sustained for weeks to months), with effect sizes that are consistently modest.

The label patterns you will see

Resveratrol product labels split into a few recognizable patterns. Only some of them are honest about what is in the bottle.

Label pattern one: "Resveratrol 500 mg" with no isomer disclosure. The 500 mg number likely includes both trans and cis isomers plus other stilbenes and impurities from the source extract. The trans-resveratrol content — the only biologically active fraction — is typically 20-50% of the labeled number, so 100-250 mg of active compound per capsule. The label is not lying; it is also not useful for dose math.

Label pattern two: "Trans-Resveratrol 500 mg" or "Resveratrol (98% trans) 500 mg." This is the honest label. The 500 mg is the active isomer, and the standardization is disclosed. Products at this labeling grade tend to cost more per bottle because trans-standardized material costs more to source and verify.

Label pattern three: "Japanese Knotweed Extract 500 mg (standardized to 50% trans-resveratrol)." This is a common source disclosure. Japanese knotweed root (Polygonum cuspidatum) is the highest-yield natural source of resveratrol and is where most commercial extract comes from — grape-skin extract is possible but much more expensive per milligram of resveratrol. The math on this label: 500 mg extract × 50% trans-resveratrol = 250 mg active per capsule. Fine if the math is transparent.

Label pattern four: "Resveratrol Complex 1500 mg" (proprietary blend). This is the label pattern to walk away from. "Complex" and "blend" typically hide the fact that most of the 1500 mg is grape seed extract, red wine extract, or other polyphenols, and the actual resveratrol content is a small fraction that the label does not disclose. The 1500 mg number sells; the 80 mg of actual trans-resveratrol inside does not. See proprietary blends are where underdosing hides.

Label pattern five: "Micronized" or "Enhanced Absorption" or "Liposomal" claims. Discussed in detail below. These are attempts to work around the bioavailability problem, and some of them do modestly change the pharmacokinetics. None of them turn oral resveratrol into a well-absorbed drug; they turn a 5% delivery rate into a 10-15% delivery rate, sometimes. The label claims often overstate the effect.

The "enhanced absorption" formulations: what they actually do

The bioavailability problem has driven a wave of formulation attempts, each with its own price premium and its own set of claims. Here is what the pharmacokinetic literature actually shows for each.

Micronized resveratrol. Reducing particle size increases surface area and dissolution rate, which can modestly increase absorption. Studies of micronized formulations show peak plasma concentrations 1.5 to 3 times higher than standard-particle-size resveratrol at the same oral dose. This is a real effect, but "3x higher" of a starting point in the 10-40 nanomolar range still lands well below any concentration that matters mechanistically. Worth a modest premium if you are taking resveratrol at all.

Liposomal resveratrol. Encapsulation of resveratrol in phospholipid liposomes can protect it from first-pass sulfation and glucuronidation, and some products claim large bioavailability improvements. The published pharmacokinetic data on liposomal resveratrol specifically is sparse and mostly comes from manufacturer-sponsored studies with methodological limitations. The reasonable estimate is a 2-5x improvement in free-resveratrol plasma concentration versus standard resveratrol at the same dose, but the shape of the curve (fast peak, fast decline) does not change fundamentally. Products vary widely in actual liposome quality; the label claim of "liposomal" tells you the intent, not the delivery.

Sustained-release (SR) resveratrol. SR formulations attempt to spread the absorption window over several hours so the plasma concentration stays low but sustained rather than peaking briefly. Some evidence suggests this may produce more consistent SIRT1 activation than a single fast-peak dose, but the total AUC (area under the curve) is not necessarily improved and the peak concentration is often lower. Reasonable in theory, mixed evidence in practice.

Piperine co-administration. Adding piperine (the active compound in black pepper) to resveratrol has been shown in some studies to increase plasma resveratrol by inhibiting the glucuronidation pathway. The effect is modest and dose-dependent; a 20 mg piperine dose combined with 500 mg resveratrol has been shown to raise peak plasma resveratrol roughly 2-fold. Cheap add-on, worth having in the formulation.

Pterostilbene. Pterostilbene is a naturally occurring methylated derivative of resveratrol found primarily in blueberries. The methylation blocks one of the main sulfation sites, and pterostilbene has substantially better oral bioavailability (roughly 4-7x) than resveratrol at equal doses in comparative studies. It has overlapping but distinct pharmacology — SIRT1 activation, antioxidant activity, some evidence in cognitive endpoints — and is not simply "better resveratrol," but for someone specifically pursuing the SIRT1 and metabolic-effect angle, pterostilbene may be a more defensible choice than resveratrol dose-for-dose. It is also more expensive per gram.

Polydatin (resveratrol-3-beta-glucoside). Polydatin is a naturally occurring resveratrol glucoside that resists sulfation and glucuronidation and is slowly hydrolyzed back to free resveratrol in circulation. It has a longer half-life and higher AUC than free resveratrol at equal doses. Less well-studied than the parent compound but has a coherent pharmacokinetic case for use.

The trial-dose landscape

The human trials that show any effect at all on cardiovascular, metabolic, or cognitive endpoints have generally used one of two dose ranges.

Low-to-moderate dose (100-500 mg/day sustained for 4-12 weeks). This range is where the cardiovascular endothelial function improvements have been most consistently shown, particularly in patients with elevated cardiovascular risk factors. Effect sizes are modest — a 3-5% improvement in flow-mediated dilation, small reductions in inflammatory markers, small improvements in insulin sensitivity in some diabetes and prediabetes trials. Nothing dramatic. Comparable in magnitude to the effect of adding a couple servings of berries or a moderate amount of dark chocolate to the diet.

High dose (1000-2500 mg/day sustained). This range has been studied in specific patient populations — Alzheimer's disease, non-alcoholic fatty liver disease, type 2 diabetes — with mixed results and a higher rate of GI side effects. The Alzheimer's trials in particular have not shown clinically meaningful cognitive benefit. The metabolic trials have shown small effects on glucose parameters in some subgroups.

Very high dose (5000 mg single-dose or short-term). Studied for tolerability and pharmacokinetics rather than efficacy. GI side effects (nausea, cramping, diarrhea) become common. Not a chronic-use dose.

The honest read on the trial base: oral resveratrol at practical doses produces modest, real, but small effects on a narrow set of endpoints, primarily in populations with pre-existing cardiovascular or metabolic risk factors. It is not a longevity pill. It is not a substitute for exercise, sleep, and diet. It is a modestly-effective polyphenol supplement whose delivered dose is far below what the mechanistic literature suggested it might be.

Whether resveratrol is worth taking at all

The transparency-first honest answer: for most people, probably not. The delivered dose from a typical 500 mg capsule is a small fraction of what the trials that showed anything used, and the trials that used higher doses have produced modest effects even at those levels. The population most likely to benefit is one with existing cardiovascular risk factors or metabolic dysregulation, and even for that group, the effect size is small.

If you are going to take it anyway, three rules:

One: buy trans-resveratrol standardized product, not "resveratrol complex" proprietary blends. The blends hide actual doses behind a bigger cumulative number. Label pattern two or three from the section above.

Two: take it with a fat-containing meal. Resveratrol absorption is enhanced by concurrent fat intake, and taking it in the fasted state increases the GI side effect risk at higher doses.

Three: consider pterostilbene as an alternative if the underlying goal is SIRT1 activation or metabolic-effect endpoints. Better bioavailability at lower doses, cleaner label patterns generally, but higher cost per gram.

And if you have serious cardiovascular or metabolic risk factors, the resveratrol conversation is a distant seventh or eighth priority behind exercise, sleep, weight management, dietary pattern, and — if indicated — the appropriate pharmacological interventions your physician manages. The polyphenol supplement conversation matters at the margins, not at the center.

The label test in 15 seconds

Pick up any resveratrol bottle. The bottle passes if:

• The label discloses trans-resveratrol content specifically, not just "resveratrol"
• The trans-resveratrol number is at least 100 mg per serving (lower doses have essentially no evidence base)
• The source is disclosed (Japanese knotweed extract or grape source, with standardization percentage)
• The formulation is either standard, micronized, or includes piperine — and is honest about which
• The product is not a proprietary "complex" or "blend" that hides the resveratrol content behind a larger cumulative number

The bottle fails if:

• Only "resveratrol" is listed with no isomer or standardization disclosure
• The dose number is over 500 mg with no explanation of the source or standardization (probably includes cis isomer and inert impurities)
• It is a proprietary blend where resveratrol is one of many ingredients and the individual doses are not listed
• The bottle makes "anti-aging" or "life extension" claims — the human evidence does not support those claims at any oral dose

Fifteen seconds, one Supplement Facts panel, one honest go/no-go read. The label pattern is the difference between a supplement that delivers what the trials studied and a bottle of expensive urinary conjugates.